Navigation Links
The 'appetite-suppressing' effect of proteins explained
Date:7/6/2012

Frequently recommended in weight-loss diets, dietary proteins have proven effectiveness thanks to their appetite-suppressing effects. A team led by Gilles Mithieux, Director of Inserm's Unit 855 "Nutrition and the Brain" in Lyon, has managed to explain the biological mechanisms behind these properties. The researchers describe in detail the chain reactions triggered by digesting proteins, sending a 'satiety' message to the brain long after a meal. Their results, published on 5 July in the Cell review, will make it possible envisage improved care for obese or overweight patients.

The team of researchers from Inserm, CNRS and the Universit Clause Bernard Lyon 1 has managed to shed light on the sensation of fullness experienced several hours after a protein-rich meal. This sensation is explained by messages exchanged between the digestive system and the brain, initiated by the dietary proteins that are mainly found in meat, fish, eggs or even some cereal-based products.

In previous studies, researchers proved that consuming dietary proteins triggers glucose synthesis in the intestine, after periods of food assimilation (a function known as gluconeogenesis). The glucose that is released in the blood circulation (portal vein) is detected by the nervous system, which sends an "appetite-suppressing" signal to the brain. Best-known in the liver and kidneys from which it supplies other organs with sugar, gluconeogenesis in the intestine sends an "appetite-suppressing" message after meals, characteristic of the sensation of "fullness".

In this new study, the researchers managed to accurately describe how digesting proteins triggers a double-loop of chain reactions involving the ventral (via the vagus nerve) and dorsal (via the spinal cord) peripheral nervous systems.

The in-depth study of biological mechanisms identified the specific receptors (μ-opioid receptors ) found in the portal vein nervous system, at the outlet of the intestine. These receptors are inhibited by oligo-peptides, produced during protein digestion.

In an initial phase, the oglio-peptides act upon the μ-opioid receptors, which send a message through the vagus nerve and the spinal chord to areas of the brain specially-designed to receive these messages.

During a second phase, the brain sends a return-message that triggers gluconeogenesis via the intestine. The intestine then sends the "appetite-suppressing" message to areas of the brain that control food intake, such as the hypothalamus

  1. Consumption of dietary proteins
  2. Protein residues (oligo-peptides) travel to the intestine in the portal vein
  3. Recognition of oligo-peptides by μ-opioid receptors
  4. Receipt of peripheral signals
  5. Gluconeogenesis induction
  6. "Appetite-suppressing" message sent to brain

Identifying these receptors and their role in intestinal gluconeogenesis paves the way to explore new avenues for the treatment of obesity. The challenge is now to determine how to act on the μ-opioid receptors to control the fullness sensation over long periods. According to Gilles Mithieux, the leading author in the study: "If used too intensely, these receptors may become insensitive. A means of activating them 'moderately' must be found, thus retaining their long-term beneficial effects on controlling food intake".


'/>"/>

Contact: Inserm Press Office
presse@inserm.fr
INSERM (Institut national de la sant et de la recherche mdicale)
Source:Eurekalert  

Related biology news :

1. Study offers new insights into the effects of stress on pregnancy
2. Scientists reconstruct pre-Columbian human effects on the Amazon Basin
3. The activity of a bacterial effector protein seen in molecular detail
4. Researchers at GW receive federal funds to study the effect earthquakes have on nuclear reactors
5. New report examines effects of trees killed by bark beetles on wildfire
6. The effect of treatment with antibiotics and vaccination against Q fever in sheep
7. Novel discovery by NUS scientists paves the way for more effective treatment of cancers
8. Lab tests show arthritis drug effective against global parasite
9. New evidence that many genes of small effect influence economic decisions and political attitudes
10. The gut could reveal effect of climate change on fish
11. WSU researchers say genes and vascular risk modify effects of aging on brain and cognition
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
The 'appetite-suppressing' effect of proteins explained
(Date:5/12/2016)... 2016 WearablesResearch.com , a brand of ... results from the Q1 wave of its quarterly wearables ... consumers, receptivity to a program where they would receive ... insurance company. "We were surprised to see ... Michael LaColla , CEO of Troubadour Research, "primarily because ...
(Date:4/28/2016)... GOTHENBURG, Sweden , April 28, 2016 ... 1,491.2 M (139.9), up 966% compared with the first quarter of ... Operating profit totaled SEK 589.1 M (loss: 18.8) and the operating ... SEK 7.12 (loss: 0.32) Cash flow from operations was ... , The 2016 revenue guidance is unchanged, SEK 7,000-8,500 M. ...
(Date:4/15/2016)... CHICAGO , April 15, 2016  A ... companies make more accurate underwriting decisions in a ... offering timely, competitively priced and high-value life insurance ... health screenings. With Force Diagnostics, rapid ... and lifestyle data readings (blood pressure, weight, pulse, ...
Breaking Biology News(10 mins):
(Date:6/27/2016)... , June 27, 2016  Liquid Biotech ... the funding of a Sponsored Research Agreement with ... tumor cells (CTCs) from cancer patients.  The funding ... CTC levels correlate with clinical outcomes in cancer ... data will then be employed to support the ...
(Date:6/24/2016)... June 24, 2016 Epic Sciences unveiled ... cancers susceptible to PARP inhibitors by targeting homologous ... (CTCs). The new test has already been incorporated ... multiple cancer types. Over 230 clinical ... response pathways, including PARP, ATM, ATR, DNA-PK and ...
(Date:6/23/2016)... ... 23, 2016 , ... Mosio, a leader in clinical research ... Recruitment and Retention Tips.” Partnering with experienced clinical research professionals, Mosio revisits the ... tools, and strategies for clinical researchers. , “The landscape of how patients receive ...
(Date:6/23/2016)... 23, 2016 /PRNewswire/ - FACIT has announced the ... biotechnology company, Propellon Therapeutics Inc. ("Propellon" or ... of a portfolio of first-in-class WDR5 inhibitors for ... as WDR5 represent an exciting class of therapies, ... medicine for cancer patients. Substantial advances have been ...
Breaking Biology Technology: